These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 577153)

  • 1. [Anti-ulcer agent pirenzepine (LS 519)--a tricyclic compound with particular physico-chemical properties (author's transl)].
    Eberlein W; Schmidt G; Reuter A; Kutter E
    Arzneimittelforschung; 1977 Feb; 27(2):356-9. PubMed ID: 577153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Inhibition of nocturnal acid secretion by pirenzepine (author's transl)].
    Dammann HG; Simon B; Müller P; Krüger HJ
    Arzneimittelforschung; 1982; 32(3):309-10. PubMed ID: 7044387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Mechanism of action of the gastric secretion inhibitor Pirenzepin].
    Hammer R; Koss FW
    Fortschr Med; 1980 Apr; 98(14):(549-54). PubMed ID: 6892811
    [No Abstract]   [Full Text] [Related]  

  • 4. The pharmacokinetic profile of pirenzepine.
    Hammer R; Koss FW
    Scand J Gastroenterol Suppl; 1979; 57():1-6. PubMed ID: 295516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformational analysis of the antiulcer drug pirenzepine. X-ray investigations, molecular mechanics and quantum mechanical calculations and comparisons with structurally or pharmacologically related compounds.
    Trummlitz G; Schmidt G; Wagner HU; Luger P
    Arzneimittelforschung; 1984; 34(8):849-59. PubMed ID: 6548635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical pharmacology of pirenzepine. Similarities with tricyclic antidepressants in antimuscarinic effects only.
    Bechtel WD; Mierau J; Pelzer H
    Arzneimittelforschung; 1986 May; 36(5):793-6. PubMed ID: 3755340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and properties of some new 11-acyl-5,11-dihydro-6H-pyrido [2,3-b] [1,4]-benzodiazepin-6-ones.
    Decorte E; Gratton G; Kovac T; Mihalić M; Comisso G; Angeli C; Toso R; Sunjić V
    Farmaco Sci; 1982 Dec; 37(12):787-96. PubMed ID: 7152014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiulcerogenic effect of a pyrido-benzodiazepine derivative (L-S 519) on experimental ulcers.
    Kitagawa H; Kurahashi K; Fujiwara M; Kohei H
    Arzneimittelforschung; 1978; 28(11):2122-7. PubMed ID: 582916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Actions of pirenzepine-dihydrochloride (LS-519 Cl) on gastric juice secretion, gastric motility and experimental gastric ulcer.
    Matsuo Y; Seki A
    Arzneimittelforschung; 1979; 29(7):1028-35. PubMed ID: 582994
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapeutic effect of pirenzepine dihydrochloride on gastric ulcer evaluated by a double-blind controlled clinical study. Phase III study.
    Ishimori A; Yamagata S
    Arzneimittelforschung; 1982; 32(5):556-65. PubMed ID: 7049190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic evaluation of selective antimuscarinic properties of pirenzepine in the rat.
    Del Soldato P; Pagani F
    Pharmacol Res Commun; 1982 Mar; 14(3):279-87. PubMed ID: 6896580
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhibition of gastrin secretion by pirenzepine (LS 519) in treatment of gastric ulcer.
    Tatsuta M; Itoh T; Okuda S; Tamura H; Baba M; Yamamura H
    Scand J Gastroenterol; 1981; 16(2):269-71. PubMed ID: 6895560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absorption, distribution and excretion of 14C-pirenzepine in rats. Accumulation characteristics after multiple dose regimen.
    Kobayashi S; Kyui S; Yoshida T; Nagakura A; Oiwa Y; Matsumura R; Kohei H
    Arzneimittelforschung; 1981; 31(4):679-90. PubMed ID: 6894697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central action of pirenzepine.
    Rogóz Z; Skuza G; Sowińska H
    Pol J Pharmacol Pharm; 1981; 33(6):615-26. PubMed ID: 6897118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postprandial pancreatic exocrine secretion in dogs after oral administration of pirenzepine dihydrochloride.
    Madrid JA; Salido GM; Martinez de Victoria E; Mañas M; Mataix FJ
    Arzneimittelforschung; 1985; 35(10):1560-2. PubMed ID: 2416323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and clinical studies on pirenzepine, a new antiulcer drug.
    Scand J Gastroenterol Suppl; 1979; 57():1-70. PubMed ID: 295517
    [No Abstract]   [Full Text] [Related]  

  • 17. Cerebro-spinal fluid concentrations of pirenzepine after therapeutic dosage.
    Jaup BH; Blomstrand C
    Scand J Gastroenterol Suppl; 1980; 66():35-7. PubMed ID: 6941375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of pirenzepine on human esophageal motility (author's transl)].
    Denis P; Galmiche JP; Gibon JF; Colin R; Pasquis P; Lefrançois R
    Gastroenterol Clin Biol; 1982 Jan; 6(1):27-31. PubMed ID: 6896038
    [No Abstract]   [Full Text] [Related]  

  • 19. [Effect of pirenzepine and atropine on the transmural gastric mucosal potential difference (author's transl)].
    von Kleist D; Staud R; Stopik D; Hampel HE
    Dtsch Z Verdau Stoffwechselkr; 1980; 40(3-4):110-4. PubMed ID: 6893819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of central gastric antisecretory effects of desmethylimipramine, doxepin and pirenzepine in rats.
    Pendleton RG; Williams M; Chung C; Cook P; Risley E
    Naunyn Schmiedebergs Arch Pharmacol; 1984 Jun; 326(3):210-4. PubMed ID: 6547998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.